216 related articles for article (PubMed ID: 33333147)
1. Estimated GFR Variability and Risk of Cardiovascular Events and Mortality in SPRINT (Systolic Blood Pressure Intervention Trial).
Malhotra R; Katz R; Jotwani V; Agarwal A; Cohen DL; Cushman WC; Ishani A; Killeen AA; Kitzman DW; Oparil S; Papademetriou V; Parikh CR; Raphael KL; Rocco MV; Tamariz LJ; Whelton PK; Wright JT; Shlipak MG; Ix JH
Am J Kidney Dis; 2021 Jul; 78(1):48-56. PubMed ID: 33333147
[TBL] [Abstract][Full Text] [Related]
2. Estimated Kidney Tubular Secretion and Kidney, Cardiovascular, and Mortality Outcomes in CKD: The Systolic Blood Pressure Intervention Trial.
Ascher SB; Shlipak MG; Katz R; Bullen AL; Scherzer R; Hallan SI; Cheung AK; Raphael KL; Estrella MM; Jotwani VK; Seegmiller JC; Ix JH; Garimella PS
Kidney Med; 2022 Dec; 4(12):100546. PubMed ID: 36507053
[TBL] [Abstract][Full Text] [Related]
3. Markers of kidney tubule function and risk of cardiovascular disease events and mortality in the SPRINT trial.
Garimella PS; Lee AK; Ambrosius WT; Bhatt U; Cheung AK; Chonchol M; Craven T; Hawfield AT; Jotwani V; Killeen A; Punzi H; Sarnak MJ; Wall BM; Ix JH; Shlipak MG
Eur Heart J; 2019 Nov; 40(42):3486-3493. PubMed ID: 31257404
[TBL] [Abstract][Full Text] [Related]
4. Effects of Stenting for Atherosclerotic Renal Artery Stenosis on eGFR and Predictors of Clinical Events in the CORAL Trial.
Tuttle KR; Dworkin LD; Henrich W; Greco BA; Steffes M; Tobe S; Shapiro JI; Jamerson K; Lyass A; Pencina K; Massaro JM; D'Agostino RB; Cutlip DE; Murphy TP; Cooper CJ
Clin J Am Soc Nephrol; 2016 Jul; 11(7):1180-1188. PubMed ID: 27225988
[TBL] [Abstract][Full Text] [Related]
5. Urinary Biomarkers of Tubular Damage Are Associated with Mortality but Not Cardiovascular Risk among Systolic Blood Pressure Intervention Trial Participants with Chronic Kidney Disease.
Jotwani VK; Lee AK; Estrella MM; Katz R; Garimella PS; Malhotra R; Rifkin DE; Ambrosius W; Freedman BI; Cheung AK; Raphael KL; Drawz P; Neyra JA; Oparil S; Punzi H; Shlipak MG; Ix JH;
Am J Nephrol; 2019; 49(5):346-355. PubMed ID: 30939472
[TBL] [Abstract][Full Text] [Related]
6. Association of Urinary Dickkopf-3 Levels with Cardiovascular Events and Kidney Disease Progression in Systolic Blood Pressure Intervention Trial.
Peschard VG; Scherzer R; Katz R; Chen TK; Bullen AL; Campos K; Estrella MM; Ix JH; Shlipak MG
Kidney360; 2024 May; 5(5):690-697. PubMed ID: 38472135
[TBL] [Abstract][Full Text] [Related]
7. Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial.
Weiner DE; Park M; Tighiouart H; Joseph AA; Carpenter MA; Goyal N; House AA; Hsu CY; Ix JH; Jacques PF; Kew CE; Kim SJ; Kusek JW; Pesavento TE; Pfeffer MA; Smith SR; Weir MR; Levey AS; Bostom AG
Am J Kidney Dis; 2019 Jan; 73(1):51-61. PubMed ID: 30037726
[TBL] [Abstract][Full Text] [Related]
8. Kidney Function as Risk Factor and Predictor of Cardiovascular Outcomes and Mortality Among Older Adults.
Kühn A; van der Giet M; Kuhlmann MK; Martus P; Mielke N; Ebert N; Schaeffner ES
Am J Kidney Dis; 2021 Mar; 77(3):386-396.e1. PubMed ID: 33197533
[TBL] [Abstract][Full Text] [Related]
9. Cystatin C-based estimated GFR and albuminuria are independently associated with all-cause and CVD mortality in Korean population: The Dong-gu Study.
Kim HY; Kweon SS; Lee YH; Ryu SY; Nam HS; Shin MH; Park KS; Choi SW
Maturitas; 2021 Jan; 143():178-183. PubMed ID: 33308626
[TBL] [Abstract][Full Text] [Related]
10. The kidney and cardiovascular outcome trials.
Bloomgarden Z
J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
[TBL] [Abstract][Full Text] [Related]
11. The Difference Between Cystatin C- and Creatinine-Based Estimated GFR and Associations With Frailty and Adverse Outcomes: A Cohort Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT).
Potok OA; Ix JH; Shlipak MG; Katz R; Hawfield AT; Rocco MV; Ambrosius WT; Cho ME; Pajewski NM; Rastogi A; Rifkin DE
Am J Kidney Dis; 2020 Dec; 76(6):765-774. PubMed ID: 32682697
[TBL] [Abstract][Full Text] [Related]
12. Mortality risks for all causes and cardiovascular diseases and reduced GFR in a middle-aged working population in Taiwan.
Cheng TY; Wen SF; Astor BC; Tao XG; Samet JM; Wen CP
Am J Kidney Dis; 2008 Dec; 52(6):1051-60. PubMed ID: 18706747
[TBL] [Abstract][Full Text] [Related]
13. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
[TBL] [Abstract][Full Text] [Related]
14. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Drury PL; Ting R; Zannino D; Ehnholm C; Flack J; Whiting M; Fassett R; Ansquer JC; Dixon P; Davis TM; Pardy C; Colman P; Keech A
Diabetologia; 2011 Jan; 54(1):32-43. PubMed ID: 20668832
[TBL] [Abstract][Full Text] [Related]
15. Cognitive Function and Kidney Disease: Baseline Data From the Systolic Blood Pressure Intervention Trial (SPRINT).
Weiner DE; Gaussoin SA; Nord J; Auchus AP; Chelune GJ; Chonchol M; Coker L; Haley WE; Killeen AA; Kimmel PL; Lerner AJ; Oparil S; Saklayen MG; Slinin YM; Wright CB; Williamson JD; Kurella Tamura M;
Am J Kidney Dis; 2017 Sep; 70(3):357-367. PubMed ID: 28606731
[TBL] [Abstract][Full Text] [Related]
16. Association of serum uromodulin with mortality and cardiovascular disease in the elderly-the Cardiovascular Health Study.
Steubl D; Buzkova P; Garimella PS; Ix JH; Devarajan P; Bennett MR; Chaves PHM; Shlipak MG; Bansal N; Sarnak MJ
Nephrol Dial Transplant; 2020 Aug; 35(8):1399-1405. PubMed ID: 30903163
[TBL] [Abstract][Full Text] [Related]
17. Chronic kidney disease, cardiovascular disease and mortality: A prospective cohort study in a multi-ethnic Asian population.
Lim CC; Teo BW; Ong PG; Cheung CY; Lim SC; Chow KY; Meng CC; Lee J; Tai ES; Wong TY; Sabanayagam C
Eur J Prev Cardiol; 2015 Aug; 22(8):1018-26. PubMed ID: 24857889
[TBL] [Abstract][Full Text] [Related]
18. PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINT.
Ginsberg C; Craven TE; Chonchol MB; Cheung AK; Sarnak MJ; Ambrosius WT; Killeen AA; Raphael KL; Bhatt UY; Chen J; Chertow GM; Freedman BI; Oparil S; Papademetriou V; Wall BM; Wright CB; Ix JH; Shlipak MG;
Clin J Am Soc Nephrol; 2018 Dec; 13(12):1816-1824. PubMed ID: 30425104
[TBL] [Abstract][Full Text] [Related]
19. GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD.
Tuegel C; Katz R; Alam M; Bhat Z; Bellovich K; de Boer I; Brosius F; Gadegbeku C; Gipson D; Hawkins J; Himmelfarb J; Ju W; Kestenbaum B; Kretzler M; Robinson-Cohen C; Steigerwalt S; Bansal N
Am J Kidney Dis; 2018 Oct; 72(4):519-528. PubMed ID: 29866459
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
